Free shipping on all orders $250CAD or more within Canada.

BPC-157/TB500 10mg/10mg

  • HOME
  • |
  • BPC-157/TB500 10mg/10mg

BPC-157/TB500 10mg/10mg

SKU BB202606A

BPC-157 / TB-500 is a dual-peptide research blend combining BPC-157, a synthetic 15-amino-acid peptide, with TB-500, a research peptide associated with thymosin beta-4 biology. The combination is studied in experimental models involving tissue repair, cellular migration, angiogenic signalling, inflammatory pathways and recovery following tissue injury.

BPC-157 research has focused on gastrointestinal tissue, tendon, ligament, muscle, vascular and wound-repair models, while thymosin beta-4 research has examined actin regulation, endothelial-cell migration, angiogenesis and tissue-remodelling pathways. Together, these compounds provide researchers with a complementary model for investigating multiple biological processes involved in tissue maintenance and repair.

This material is intended for laboratory research only, is not authorized by Health Canada for human therapeutic use, and is not intended for human or veterinary administration.


CA$79.99

In Stock

Choose a kit option to save more, or skip this and buy individually above.

Save 9%
2 Vials x 20mg
CA$145.00 CA$160.00
Save 13%
4 Vials x 20mg
CA$280.00 CA$320.00
Save 20%
6 Vials x 20mg
CA$385.00 CA$480.00
Save 30%
10 Vials x 20mg
CA$560.00 CA$800.00
HPLC Purity Verified
Batch Documented
LC-MS Confirmation Available
2°C Storage

*LC-MS identity confirmation may be performed when analytical review indicates conflicting, atypical, or inconclusive results.

What is BPC-157 / TB-500?

BPC-157 / TB-500 is a combined research formulation containing two peptides studied for their involvement in cellular repair, tissue remodelling and recovery-related biological pathways.

BPC-157 is a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV and a molecular weight of approximately 1,419 Da. Experimental research has investigated BPC-157 in models involving gastrointestinal tissue, muscle, tendon, ligament, vascular tissue, nerves and wound repair.

TB-500 is commonly associated with research involving thymosin beta-4 biology. Thymosin beta-4 is a naturally occurring 43-amino-acid peptide involved in actin regulation, cell migration, angiogenic signalling and tissue-remodelling processes.

Combining these two research compounds provides a model for studying different but potentially complementary mechanisms associated with cellular migration, vascular responses, tissue organisation and repair.

BPC-157 Research

BPC-157 has received considerable experimental attention for its potential influence on tissue-protective and repair-associated pathways.

Preclinical studies have examined BPC-157 in models involving tendon and ligament injury, skeletal muscle damage, gastrointestinal lesions, vascular disruption and nervous-system injury. Proposed mechanisms investigated in these models include modulation of nitric-oxide signalling, angiogenic pathways, cellular migration and inflammatory responses.

Much of the available evidence remains derived from animal and laboratory research. Human evidence is comparatively limited, and recent scientific reviews continue to identify major gaps in standardized pharmacology, formulation, pharmacokinetics and controlled clinical investigation.

TB-500 and Thymosin Beta-4 Research

Thymosin beta-4 is a naturally occurring peptide found in many mammalian tissues and is particularly well known for its interaction with actin.

Actin is a fundamental component of the cellular cytoskeleton and contributes to cell movement, structural organization and tissue remodelling. Thymosin beta-4 binds monomeric G-actin and participates in regulation of actin availability within cells.

Research has also associated thymosin beta-4 with endothelial-cell migration, formation of vascular structures and wound-repair mechanisms. Experimental studies have identified specific regions of the thymosin beta-4 molecule associated with cellular migration and angiogenic activity.

Tissue Repair and Cellular Migration Research

Cellular migration is an essential component of normal tissue repair. Cells must move into damaged regions, reorganize extracellular structures and participate in rebuilding tissue.

BPC-157 and thymosin beta-4 have both been investigated independently in research involving these processes.

Thymosin beta-4 has demonstrated effects involving keratinocyte and endothelial-cell migration, actin organization and vascular development in experimental systems. BPC-157 research has separately examined cellular and vascular responses during wound and tissue-repair models.

The combination therefore provides a useful experimental model for investigating multiple signalling pathways involved in tissue remodelling rather than relying on a single molecular mechanism.

Angiogenesis and Vascular Research

Angiogenesis is the biological process through which new blood vessels develop from existing vascular structures.

Thymosin beta-4 has been studied extensively for its relationship with endothelial-cell migration, adhesion, vascular sprouting and formation of capillary-like structures. Its actin-binding region has also been associated experimentally with angiogenic activity.

BPC-157 research has likewise examined vascular signalling and vascular responses in several experimental injury models.

These observations have made vascular remodelling and angiogenesis an important area of investigation when studying these peptides.

Tendon, Ligament and Muscle Research

Experimental BPC-157 research includes models involving tendon, ligament and skeletal-muscle injury.

Researchers have examined changes in fibroblast activity, tissue organization, vascular response and functional recovery following experimentally induced tissue damage.

Thymosin beta-4 research provides an additional mechanistic area of interest because actin regulation and cell migration play central roles in tissue restructuring after injury.

These findings are primarily experimental and should not be interpreted as establishing a therapeutic effect in humans.

Wound-Healing Research

Thymosin beta-4 has an established experimental research history involving dermal and corneal wound healing.

Studies have examined its effects on cellular migration, inflammation, vascular development and tissue remodelling. Preclinical models and limited controlled clinical research involving thymosin beta-4 formulations have investigated dermal repair.

BPC-157 has separately been investigated in numerous experimental injury models, making wound and tissue-repair biology an area of overlapping scientific interest between the two compounds.

Important Evidence Limitations

BPC-157 and thymosin beta-4 should not be considered equivalent in terms of available evidence.

BPC-157 research remains predominantly preclinical, with only very limited published human data.

Thymosin beta-4 has a broader published literature and has undergone some human investigation, but results involving pharmaceutical-grade thymosin beta-4 preparations cannot automatically be extrapolated to independently manufactured TB-500 research materials.

The commercial term TB-500 may also be used for different thymosin beta-4-derived materials. The exact peptide sequence and molecular identity of a particular TB-500 sample should therefore be established through supplier documentation and appropriate analytical testing rather than assumed from the product name alone.

HPLC purity does not independently establish peptide identity, total peptide quantity, sterility or endotoxin status. These characteristics require separate analytical methods where applicable.

For laboratory research only. Not for human or veterinary use.

BPC-157 / TB-500 Product Specifications

Product Identification

Product name: BPC-157 / TB-500

Compound type: Dual-peptide research blend

Research classification: Tissue-repair and cellular-signalling research peptides

Research category: Tissue remodelling, cellular migration, angiogenic signalling and repair-pathway research

Total nominal content: 20 mg

BPC-157 content: 10 mg

TB-500 content: 10 mg

Format: Lyophilized research material supplied in a sealed laboratory vial

Intended classification: Laboratory research reagent

BPC-157 Component

Name: BPC-157

Peptide length: 15 amino acids

Amino-acid sequence: GEPPPGKPADDAGLV

Approximate molecular weight: 1,419 Da

Structural class: Synthetic linear peptide

Research areas: Tissue-repair pathways, gastrointestinal research, vascular signalling, cellular migration, tendon and ligament models and inflammatory-response research.

TB-500 Component

Name: TB-500

Research association: Thymosin beta-4-related research

Research areas: Actin regulation, cellular migration, angiogenic signalling, endothelial-cell biology and tissue-remodelling research

Thymosin beta-4 itself is a naturally occurring 43-amino-acid peptide of approximately 5 kDa with an acetylated N-terminus.

Because the designation TB-500 is used commercially for more than one thymosin beta-4-related peptide preparation, the precise amino-acid sequence and molecular mass of the TB-500 component should be taken from the applicable raw-material specification or confirmed by analytical identity testing.

Physical Specifications

Physical form: Lyophilized powder

Typical appearance: White to off-white lyophilized material

Presentation: Sealed laboratory vial

Nominal blend ratio: 1:1 by labelled peptide mass

Nominal total content: 20 mg

Nominal composition: 10 mg BPC-157 + 10 mg TB-500

Physical appearance alone does not establish peptide identity, purity or quantity.

Analytical Specifications

Primary purity assessment: High-performance liquid chromatography (HPLC)

Identity assessment: Mass-spectrometric or other suitable identity analysis where specifically performed

Purity reporting: Individual or combined batch-specific analytical results as applicable

Quantity/content determination: Independent quantitative analysis where performed

Blend identification: Both peptide components should be analytically identifiable when the testing method is capable of resolving the individual compounds

HPLC chromatographic purity should not independently be interpreted as confirmation of total vial content or confirmation that both components are present at the labelled quantities.

Batch-Testing Information

Each production batch should be identified using its individual lot or batch number and linked directly to the corresponding analytical documentation.

Where performed, batch documentation may include:

  • HPLC chromatographic analysis
  • identity testing for BPC-157
  • identity testing for TB-500
  • mass-spectrometric characterization
  • quantitative content determination
  • blend-ratio verification
  • analytical laboratory information
  • sample or batch identification
  • date of testing
  • applicable Certificate of Analysis

Only analytical tests actually performed on the applicable batch should be represented as completed.

Sterility, endotoxin, microbial or pharmaceutical-quality characteristics should not be implied unless specifically evaluated using an appropriate validated analytical method.

Storage Specifications

Recommended storage: 2–8°C

Light exposure: Protect from unnecessary light exposure

Moisture: Maintain in a sealed, dry environment

Container: Keep vial securely closed until required for laboratory analysis

Stability: Batch-specific stability should not be assumed beyond available analytical or manufacturer documentation

Storage information relates solely to preservation of laboratory research material and does not constitute preparation or administration instructions.

Intended Use and Restrictions

BPC-157 / TB-500 supplied under this specification is intended exclusively for:

  • laboratory research
  • analytical testing
  • peptide-characterization studies
  • cellular-migration research
  • tissue-remodelling research
  • angiogenic-signalling research
  • biochemical and molecular research
  • qualified scientific investigation

Not for human consumption.

Not for human or veterinary use.

Not intended for diagnosis, treatment, cure or prevention of disease.

Not represented as sterile or suitable for injection unless such characteristics have been independently established through appropriate validated testing.

Documentation Notice

Product specifications describe the general identity and research classification of the BPC-157 / TB-500 blend.

Actual identity, purity, quantity, blend ratio and other analytical characteristics are batch-specific and should be determined from the Certificate of Analysis and supporting laboratory documentation for the applicable lot.

Published research involving BPC-157 or thymosin beta-4 should not be interpreted as analytical verification or clinical validation of independently supplied BPC-157 / TB-500 research material.

For laboratory research only. Not for human or veterinary use.

Certificates & Lab Reports

TESTING METHODOLOGY

Each batch undergoes analytical review using validated laboratory procedures. HPLC testing is utilized to assess purity and compare the sample profile against established reference standards. Where additional verification is warranted, LC-MS analysis may be performed to support compound identity confirmation.

OUR ANALYTICAL VERIFICATION PROGRAM

  • Primary Testing: HPLC purity analysis and reference comparison
  • Identity Confirmation: LC-MS performed when indicated*
  • Quality Standards: Batch traceability, analytical documentation, third-party testing and storage procedures

*See LC-MS Confirmation Information for full details.

Every batch supplied by Vanguard Compound Research is assigned a unique batch number and maintained under documented quality-control procedures with supporting analytical documentation available upon request.

SHIPPING & FULFILLMENT

FULFILLMENT INFORMATION
Ships from Canada

All orders ship from within Canada.

Batch Documentation Available

Batch records and analytical documentation may be provided for qualifying products.

Secure Packaging

Products are packaged securely to ensure safe delivery.

Tracking Provided

Tracking information is provided for every shipment.

Temperature-Conscious Handling

Frozen or ambient-safe packaging used as appropriate.

All Vanguard Compound Research orders are shipped directly from within Canada, ensuring efficient delivery, reliable service, and consistent quality-control from fulfillment to arrival.

Canadian Researchers Benefit From:

  • Domestic shipping with no customs delays
  • Batch-specific third-party laboratory testing
  • Full lot number traceability on every product
  • Access to batch-specific Certificates of Analysis (COAs)
  • Dedicated customer support

Canada-Wide Fulfillment:

  • Orders processed Monday through Friday
  • Shipments dispatched throughout Canada
  • Discreet and secure packaging
  • Tracking provided with every shipment

Batch Documentation & Testing

Products are maintained under documented quality-control procedures to help ensure quality, consistency, and transparency.

  • HPLC purity analysis
  • Reference-standard comparison
  • Additional verification procedures (e.g. LC-MS confirmation) may be performed where warranted
  • Lot number traceability

Each product is assigned a unique lot number, allowing researchers to match their item directly to its corresponding Certificate of Analysis (COA).

Analytical Documentation

Supporting analytical documentation may be available for qualifying products, including batch-specific quality records and testing information.

Documentation may include:
  • Batch Number
  • Analytical Results
  • Traceability Records
  • Storage Information

RELATED PRODUCTS